Psoriatic Disease News

Rheumatologists should turn to biologics as usual treatment in patients with psoriatic arthritis who demonstrate an inadequate response to methotrexate, according to new EULAR recommendations.

Patients with psoriatic arthritis who use guselkumab are more likely to experience meaningful improvements in fatigue and pain if they achieve resolution of enthesitis or dactylitis, according to data published in Clinical Rheumatology.

The long-term adjudicated suicidal ideation and behavior rate in patients with psoriasis treated with bimekizumab was low and within general psoriasis population ranges, according to a study.

ARCA biopharma and Oruka Therapeutics have entered into a definitive merger agreement and will now operate under Oruka Therapeutics, ARCA announced in a press release.

Healio has compiled March’s most-read news in dermatology.

Patients with psoriatic arthritis in Canada face “substantial burden and unmet need” for improved treatments, as nearly 75% fail to achieve minimal disease activity within 6 months of starting advanced therapy, according to data.

Treating psoriasis with oral roflumilast may induce weight loss, positioning the drug as a potentially attractive alternative for patients with psoriasis, according to a study.

The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.

Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.

The FDA has approved an expanded indication for Spevigo injection to treat generalized pustular psoriasis in pediatric patients aged 12 years and older weighing 40 kg or more, Boehringer Ingelheim announced in a press release.